Cingulate Inc
CING3.970USD
+0.110+2.85%
收盤 12/19, 16:00（美東）報價延遲15分鐘
23.73M總市值
虧損本益比TTM
關於 Cingulate Inc 公司
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Cingulate Inc簡介
公司代碼CING
公司名稱Cingulate Inc
上市日期Oct 07, 2021
CEOCallahan (Jennifer L)
員工數量13
證券類型Ordinary Share
年結日Oct 07
公司地址1901 W. 47Th Place
城市KANSAS CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編66205
電話19139422300
網址https://www.cingulate.com/
公司代碼CING
上市日期Oct 07, 2021
CEOCallahan (Jennifer L)
Cingulate Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Werth Family Investment Associates LLC
1.45%
Kestra Advisory Services, LLC
1.39%
The Vanguard Group, Inc.
1.09%
Geode Capital Management, L.L.C.
0.63%
Quantum Private Wealth, LLC
0.36%
其他
95.08%
持股股東
持股股東
佔比
Werth Family Investment Associates LLC
1.45%
Kestra Advisory Services, LLC
1.39%
The Vanguard Group, Inc.
1.09%
Geode Capital Management, L.L.C.
0.63%
Quantum Private Wealth, LLC
0.36%
其他
95.08%
股東類型
持股股東
佔比
Investment Advisor
3.35%
Corporation
1.50%
Investment Advisor/Hedge Fund
0.75%
Research Firm
0.27%
其他
94.13%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
33
295.34K
5.70%
--
2025Q3
44
295.34K
6.89%
+113.00
2025Q2
41
295.23K
5.36%
+158.62K
2025Q1
38
136.60K
4.92%
-48.84K
2024Q4
38
91.23K
3.95%
+40.70K
2024Q3
38
50.54K
3.01%
-30.23K
2024Q2
36
80.24K
1.97%
+46.92K
2024Q1
36
33.32K
1.85%
+25.60K
2023Q4
33
318.00
10.05%
-5.36K
2023Q3
30
5.68K
6.07%
+3.89K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Werth Family Investment Associates LLC
97.99K
1.75%
--
--
Aug 01, 2025
The Vanguard Group, Inc.
35.38K
0.63%
+24.62K
+228.78%
Jun 30, 2025
Geode Capital Management, L.L.C.
32.16K
0.57%
+1.76K
+5.78%
Jun 30, 2025
Quantum Private Wealth, LLC
10.00K
0.18%
--
--
Jun 30, 2025
LPL Financial LLC
12.18K
0.22%
+12.18K
--
Jun 30, 2025
Virtu Americas LLC
13.35K
0.24%
+13.35K
--
Jun 30, 2025
BofA Global Research (US)
7.50K
0.13%
+5.54K
+283.09%
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
公告日期
類型
比率
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
常見問題
Cingulate Inc的前五大股東是誰？
Cingulate Inc的前五大股東如下：
Werth Family Investment Associates LLC持有股份：97.99K佔總股份比例：1.75%。
The Vanguard Group, Inc.持有股份：35.38K佔總股份比例：0.63%。
Geode Capital Management, L.L.C.持有股份：32.16K佔總股份比例：0.57%。
Quantum Private Wealth, LLC持有股份：10.00K佔總股份比例：0.18%。
LPL Financial LLC持有股份：12.18K佔總股份比例：0.22%。
Werth Family Investment Associates LLC持有股份：97.99K佔總股份比例：1.75%。
The Vanguard Group, Inc.持有股份：35.38K佔總股份比例：0.63%。
Geode Capital Management, L.L.C.持有股份：32.16K佔總股份比例：0.57%。
Quantum Private Wealth, LLC持有股份：10.00K佔總股份比例：0.18%。
LPL Financial LLC持有股份：12.18K佔總股份比例：0.22%。
Cingulate Inc的前三大股東類型是什麼？
Cingulate Inc 的前三大股東類型分別是：
Werth Family Investment Associates LLC
Kestra Advisory Services, LLC
The Vanguard Group, Inc.
Werth Family Investment Associates LLC
Kestra Advisory Services, LLC
The Vanguard Group, Inc.
有多少機構持有Cingulate Inc(CING)的股份？
截至2025Q4，共有33家機構持有Cingulate Inc的股份，合計持有的股份價值約為295.34K，占公司總股份的5.70% 。與2025Q3相比，機構持股有所增加，增幅為-1.19%。
哪個業務部門對Cingulate Inc的收入貢獻最大？
在--，--業務部門對Cingulate Inc的收入貢獻最大，創收--，占總收入的--% 。
